Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P3091
Share Class Description:
TCRT: Ordinary SharesTotal Employee Number:
1Description
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.68 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -689.86 | |||||
Beneish M-Score | -6.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -88.6 | |||||
3-Year EBITDA Growth Rate | 53.8 | |||||
3-Year EPS without NRI Growth Rate | 56.3 | |||||
3-Year FCF Growth Rate | 57.8 | |||||
3-Year Book Growth Rate | -66.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.24 | |||||
9-Day RSI | 38.32 | |||||
14-Day RSI | 39.4 | |||||
3-1 Month Momentum % | -22.93 | |||||
6-1 Month Momentum % | -31.25 | |||||
12-1 Month Momentum % | -50.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.63 | |||||
Cash Ratio | 0.59 | |||||
Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -138166.67 | |||||
Net Margin % | -136966.67 | |||||
EBITDA Margin % | -137666.67 | |||||
FCF Margin % | -104266.67 | |||||
OCF Margin % | -104266.67 | |||||
ROE % | -187.4 | |||||
ROA % | -133.17 | |||||
ROIC % | -414.42 | |||||
3-Year ROIIC % | -108.27 | |||||
ROC (Joel Greenblatt) % | -4273.2 | |||||
ROCE % | -189.04 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2150 | |||||
PB Ratio | 3.98 | |||||
Price-to-Tangible-Book | 3.98 | |||||
EV-to-EBIT | -1.18 | |||||
EV-to-EBITDA | -1.19 | |||||
EV-to-Revenue | 1632.67 | |||||
EV-to-Forward-Revenue | 4293.85 | |||||
EV-to-FCF | -1.57 | |||||
Price-to-GF-Value | 3.12 | |||||
| Price-to-Net-Current-Asset-Value | 13.44 | |||||
Earnings Yield (Greenblatt) % | -84.75 | |||||
FCF Yield % | -59.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCRT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alaunos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.003 | ||
| EPS (TTM) ($) | -2.13 | ||
| Beta | 1.5735 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.42 | ||
| Volatility % | 120.93 | ||
| 14-Day RSI | 39.4 | ||
| 14-Day ATR ($) | 0.148423 | ||
| 20-Day SMA ($) | 2.373 | ||
| 12-1 Month Momentum % | -50.71 | ||
| 52-Week Range ($) | 1.67 - 6.2 | ||
| Shares Outstanding (Mil) | 2.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alaunos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alaunos Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 141 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 50 days | ||
| General meeting for 2026 | 2026-07-03 09:00 | In 9 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.52 (-0.40%) | ||
| Annual report for 2025 | 2026-03-31 | 2.82 (-5.05%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 2.85 (-3.39%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.39 (-5.20%) | ||
| General meeting for 2025 | 2025-07-03 09:00 | 5.06 (+0.76%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 2.89 (+2.12%) | ||
| Annual report for 2024 | 2025-03-31 | 1.46 (-3.95%) |
Show
Entries
Alaunos Therapeutics Inc Frequently Asked Questions
What is Alaunos Therapeutics Inc(TCRT)'s stock price today?
The current price of TCRT is $2.15. The 52 week high of TCRT is $6.20 and 52 week low is $1.67.
When is next earnings date of Alaunos Therapeutics Inc(TCRT)?
The next earnings date of Alaunos Therapeutics Inc(TCRT) is 2026-08-14 Est..
Does Alaunos Therapeutics Inc(TCRT) pay dividends? If so, how much?
Alaunos Therapeutics Inc(TCRT) does not pay dividend.
Guru Commentaries on NAS:TCRT
No articles.
Press Release
Articles on Alaunos Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers